MEDADVISOR (MDR) reported 18% growth with operating revenue of $75.5m for H1 FY24 exceeding its guidance range, with a 13% increase in gross profit to $43.5m on the previous corresponding period (PCP).
The company's second quarter FY24 operating revenue was $50.2m, up 14% on PCP, with the US up 14% to $44.9m and ANZ up 13% to $5.3m.
The company's gross profit was up 5% to $27.7m, with a gross margin of 55.2%, down 4.7 ppts on PCP.
MedAdvisor Solutions' digital offerings and data-driven insights will play a crucial role in supporting the delivery of expanded services under the North Queensland pilot.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jan 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jan 24
